RNA interference: New therapeutics in allergic diseases
Journal
Current Gene Therapy
Journal Volume
8
Journal Issue
4
Pages
236-246
Date Issued
2008
Author(s)
Lee C.-C.
Abstract
Since the RNAi mechanisms were established in 1990, the rapid progression of RNAi application from animal to clinical trails in human diseases has shown its enormous therapeutic potential. In this review, RNAi therapeutics in allergic diseases is discussed, from RNAi mechanisms and design to challenges and potential targets in allergic diseases. Current reported studies on investigating RNAi therapy in vitro and in vivo are also reviewed. Although there are promising studies in RNAi-based therapy, understanding further the detailed mechanisms of RNAi-based therapy and investigating more effective delivery methods are required for future development. ? 2008 Bentham Science Publishers Ltd.
Subjects
Allergy; Cytokine; Gene therapy; RNAi; shRNA; siRNA; Susceptibility genes; Transcription factor
SDGs
Other Subjects
adenovirus vector; double stranded RNA; eotaxin; intercellular adhesion molecule 1 antibody; interleukin 13; interleukin 4; interleukin 4 receptor alpha; interleukin 5; lentivirus vector; microRNA; parvovirus vector; short hairpin RNA; small interfering RNA; STAT6 protein; toll like receptor; transcription factor GATA 3; very late activation antigen 4; virus vector; allergic disease; asthma; Crohn disease; cytokine production; cytokine release; drug mechanism; drug potency; gene expression; gene expression regulation; gene silencing; gene targeting; genetic susceptibility; genetic transfection; human; Human immunodeficiency virus infection; liposomal gene delivery system; low drug dose; nonhuman; nonviral gene therapy; review; RNA interference; single nucleotide polymorphism; Th2 cell; transcription initiation; viral gene delivery system; Animals; Humans; Hypersensitivity; MicroRNAs; RNA Interference; RNA, Small Interfering; Animalia
Type
review